Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant in adults with ACTH-dependent Cushing’s syndrome
ISRCTN13593692Phase 3Not yet recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Nov 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of atumelnant in ACTH-dependent Cushing's syndrome (7 arms), sponsored by Crinetics Pharmaceuticals. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
atumelnant
03
Conditions
ACTH-dependent Cushing's syndrome
Beyond the preview
Go deeper on ISRCTN13593692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13593692.